Active substance
Diclofenac epolamine
- SFDA 2
- US FDA 2
- US price lines 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FLECTOR EP GRANULES | 65 mg | Granules · Oral use | 20 Sachet | SAR 40.00 | NCE · Prescription | IBSA INSTITUTE BIOCHIMIQUE S.A | Valid |
| FLECTOR EP TISSUGEL 1GM PATCHES | 13-10 mg | Medicated plaster · Topical | 5 Patch | SAR 49.35 | NCE · OTC | IBSA INSTITUTE BIOCHIMIQUE S.A | Valid |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; EPIDERMOLYSIS BULLOSA; INFLUENZA-SYMPTOMATIC TREATMENT; LOW BACK PAIN; MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; NON-INFECTIOUS UVEITIS; PAIN MANAGEMENT IN CANCER PATIENTS; PERICORONITIS; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS
US FDA United States — FDA approvals (Drugs@FDA)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DICLOFENAC EPOLAMINE 1.3% PTCH | $4.70708 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 27 Mar 2026 LICART — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 FLECTOR — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.